Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020
July 30 2020 - 6:05AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the
“Company”) today announced that it will release its second quarter
2020 financial results on Tuesday, August 11, 2020, after the
markets close. Aurinia’s executive team will host a conference call
to discuss the Company’s financial results and to provide a general
business update.
The conference call and webcast is scheduled for 4:30 pm EDT on
August 11, 2020. In order to participate in the conference call,
please dial +1-877-407-9170 (Toll-free U.S. & Canada). An audio
webcast can be accessed under "News/Events” through the “Investors”
section of the Aurinia corporate website at www.auriniapharma.com.
A replay of the webcast will be available on Aurinia’s website.
ABOUT AURINIA
Aurinia Pharmaceuticals is a late-stage clinical
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are impacted
by serious diseases with a high unmet medical need. The Company is
currently seeking FDA approval of voclosporin for the treatment of
lupus nephritis (PDUFA date: January 22, 2021) and evaluating
voclosporin ophthalmic solution (VOS) in a Phase 2/3 study for the
treatment of dry eye syndrome. The Company’s head office is in
Victoria, British Columbia, its U.S. commercial hub in Rockville,
Maryland, and focuses its development efforts globally.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005288/en/
Investor Contact: Glenn Schulman, PharmD, MPH SVP,
Corporate Communications & IR gschulman@auriniapharma.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024